BrainsWay's SWIFT Deep TMS Shows 12-Month Durability in Depression Treatment
Event summary
- BrainsWay presented 12-month durability data for its SWIFT Deep TMS protocol at the Clinical TMS Society Annual Meeting on June 4-6, 2026.
- Over 80% of patients treated with SWIFT remained in remission through 12 months, with severe functional impairment dropping from 85% to 0%.
- Less than 25% of patients required medication changes or additional TMS treatments within the year.
- The study followed 65 patients from the original FDA pivotal trial, comparing SWIFT to standard Deep TMS protocols.
The big picture
BrainsWay's data reinforces the growing trend of accelerated neurostimulation protocols offering both rapid and sustained relief for treatment-resistant depression. The results position Deep TMS as a viable long-term alternative to traditional therapies, potentially expanding its market reach. The company's ability to demonstrate durable outcomes without neuronavigation equipment could lower barriers to adoption in clinical settings.
What we're watching
- Clinical Validation
- Whether the 12-month durability data will accelerate insurance reimbursement and broader adoption of SWIFT Deep TMS.
- Competitive Positioning
- How BrainsWay will leverage this data to differentiate itself in the growing neurostimulation market.
- Regulatory Expansion
- The pace at which BrainsWay can secure additional FDA clearances for other mental health indications using the SWIFT protocol.